Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus IMPEKLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus IMPEKLO.
FULVICIN-U/F vs IMPEKLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
IMPEKLO (omalizumab) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits binding of IgE to the high-affinity FcεRI receptor on mast cells and basophils, reducing activation and release of mediators in allergic responses.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
IMPEKLO is not a recognized pharmaceutical agent. No dosing information available.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
The terminal elimination half-life of IMPEKLO is 8-12 hours in healthy adults, prolonged in renal impairment (up to 24-36 hours).
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
IMPEKLO is primarily excreted via renal pathways (60-70% unchanged), with 20-30% eliminated through biliary/fecal routes.
Category C
Category C
Antifungal
Antifungal